Literature DB >> 33391836

Intracranial pressure management in patients with human immunodeficiency virus-associated cryptococcal meningitis in a resource-constrained setting.

Philasande Mkoko1,2, Jessica Du Preez2, Senlika Naidoo2,3.   

Abstract

BACKGROUND: Cryptococcal meningitis (CCM) is the leading cause of meningitis in people living with HIV (PLWH) in sub-Saharan Africa (SSA). The mortality and morbidity associated with CCM remain high. Combination of antifungal therapy, diligent management of intracranial pressure (IP) and the correct timing of the introduction of antiretroviral therapy (ART) minimise the risk of mortality and morbidity. The absence of spinal manometers in many healthcare centres in SSA challenges the accurate measurement of cerebrospinal fluid (CSF) pressure and its control.
OBJECTIVES: We hypothesised that four lumbar punctures (LPs) in the first week of the diagnosis and treatment of CCM would reduce IP such that in-hospital mortality and morbidity of HIV-associated CCM (HIV/CCM) would be significantly reduced.
METHODS: We conducted a retrospective study to assess whether receipt of four or more LPs in the first week of the diagnosis and treatment with combination antifungal therapy of HIV/CCM would be associated with the reduction of in-hospital mortality in adult PLWH.
RESULTS: From 01 January 2016 to 31 December 2016, 116 adult patients were admitted to the Dora Nginza District Hospital in Zwide, Port Elizabeth, South Africa. After exclusion of 11 (two were younger than 18 years, two had missing hospital records and seven demised or left the hospital before 7 days of hospitalisation), 105 patients were included in the analysis. The mean age was 39.4 (standard deviation [s.d.] ± 9.7) years, 64.8% were male. All were PLWH. A total of 52.4% had defaulted ART and 25.7% were ART naïve. Forty-three patients received four or more LPs (mean = 4.58 [± 0.96]) in the first week of hospitalisation with an associated in-hospital mortality of 11.6% (n = 5/43) compared with 62 patients who received less than four LPs (mean = 2.18 [± 0.80]) with an in-hospital mortality of 29% (n = 18/62) and a relative risk of 0.80 (95% CI, 0.66-0.97), p = 0.034.
CONCLUSION: In the current study of adult PLWH presenting to hospital with HIV/CCM, four or more LPs in the first 7 days following admission and the initiation of treatment were associated with a 17.4% reduction in absolute risk of in-hospital mortality and a 20% reduction in relative risk of in-hospital mortality. This mortality difference was noted in patients who survived and were in hospital at the time of the 7-day study census and persisted until the time of hospital discharge.
© 2020. The Authors.

Entities:  

Keywords:  HIV; adult PLWH; antifungal therapy; antiretroviral therapy; cryptococcal meningitis; in-hospital mortality

Year:  2020        PMID: 33391836      PMCID: PMC7756785          DOI: 10.4102/sajhivmed.v21i1.1171

Source DB:  PubMed          Journal:  South Afr J HIV Med        ISSN: 1608-9693            Impact factor:   2.744


  19 in total

1.  Management of cryptococcal meningitis with extremely high intracranial pressure in HIV-infected patients.

Authors:  Hsin-Yun Sun; Chien-Ching Hung; Shan-Chwen Chang
Journal:  Clin Infect Dis       Date:  2004-06-15       Impact factor: 9.079

2.  Cryptococcal Meningitis: Diagnosis and Management Update.

Authors:  Mahsa Abassi; David R Boulware; Joshua Rhein
Journal:  Curr Trop Med Rep       Date:  2015-06-01

3.  Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups.

Authors:  J R Graybill; J Sobel; M Saag; C van Der Horst; W Powderly; G Cloud; L Riser; R Hamill; W Dismukes
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

4.  Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: an operational research study.

Authors:  John Meda; Samuel Kalluvya; Jennifer A Downs; Awilly A Chofle; Jeremiah Seni; Benson Kidenya; Daniel W Fitzgerald; Robert N Peck
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

5.  Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.

Authors:  David R Boulware; David B Meya; Conrad Muzoora; Melissa A Rolfes; Katherine Huppler Hullsiek; Abdu Musubire; Kabanda Taseera; Henry W Nabeta; Charlotte Schutz; Darlisha A Williams; Radha Rajasingham; Joshua Rhein; Friedrich Thienemann; Melanie W Lo; Kirsten Nielsen; Tracy L Bergemann; Andrew Kambugu; Yukari C Manabe; Edward N Janoff; Paul R Bohjanen; Graeme Meintjes
Journal:  N Engl J Med       Date:  2014-06-26       Impact factor: 91.245

6.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

7.  Epidemiology of cryptococcal meningitis in the US: 1997-2009.

Authors:  Vasilios Pyrgos; Amy E Seitz; Claudia A Steiner; D Rebecca Prevots; Peter R Williamson
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

8.  Management of cryptococcal meningitis in a district hospital in KwaZulu-Natal: a clinical audit.

Authors:  Benjamin O Adeyemi; Andrew Ross
Journal:  Afr J Prim Health Care Fam Med       Date:  2014-10-13

9.  CryptoDex: a randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial.

Authors:  Jeremy Day; Darma Imran; Ahmed Rizal Ganiem; Natriana Tjahjani; Retno Wahyuningsih; Robiatul Adawiyah; David Dance; Mayfong Mayxay; Paul Newton; Rattanaphone Phetsouvanh; Sayaphet Rattanavong; Adrienne K Chan; Robert Heyderman; Joep J van Oosterhout; Wirongrong Chierakul; Nick Day; Anatoli Kamali; Freddie Kibengo; Eugene Ruzagira; Alastair Gray; David G Lalloo; Justin Beardsley; Tran Quang Binh; Tran Thi Hong Chau; Nguyen Van Vinh Chau; Ngo Thi Kim Cuc; Jeremy Farrar; Tran Tinh Hien; Nguyen Van Kinh; Laura Merson; Lan Phuong; Loc Truong Tho; Pham Thanh Thuy; Guy Thwaites; Heiman Wertheim; Marcel Wolbers
Journal:  Trials       Date:  2014-11-12       Impact factor: 2.279

10.  Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update.

Authors:  Nelesh P Govender; Graeme Meintjes; Phetho Mangena; Jeremy Nel; Samantha Potgieter; Denasha Reddy; Helena Rabie; Douglas Wilson; John Black; David Boulware; Tom Boyles; Tom Chiller; Halima Dawood; Sipho Dlamini; Thomas S Harrison; Prudence Ive; Joseph Jarvis; Alan Karstaedt; Matamela C Madua; Colin Menezes; Mahomed-Yunus S Moosa; Zaaheera Motlekar; Amir Shroufi; Sarah Lynn Stacey; Merika Tsitsi; Gilles van Cutsem; Ebrahim Variava; Michelle Venter; Rachel Wake
Journal:  South Afr J HIV Med       Date:  2019-11-08       Impact factor: 2.744

View more
  1 in total

1.  Therapeutic Lumbar Punctures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Should Opening Pressure Direct Management?

Authors:  Enock Kagimu; Nicole Engen; Kenneth Ssebambulidde; John Kasibante; Tadeo K Kiiza; Edward Mpoza; Lillian Tugume; Edwin Nuwagira; Laura Nsangi; Darlisha A Williams; Kathy Huppler Hullsiek; David R Boulware; David B Meya; Joshua Rhein; Mahsa Abassi; Abdu K Musubire
Journal:  Open Forum Infect Dis       Date:  2022-08-17       Impact factor: 4.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.